The US Senate Health, Education, Labor and Pensions Committee has approved an amendment that would provide innovative biologic drugs with 12 years protection from competition by biosimilar products.
Wall Street Journal
Sunday 19 July 2009
Senate committee vote on biosimilars
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment